
    
      Patients will receive the study drug (SENS-401 or placebo) in the form of tablets by mouth,
      twice a day (3 tablets in the morning and 3 tablets in the evening), during the first 4 weeks
      after randomization.

      SENS-401 is an investigational medicinal product. It belongs to a family of drugs known as "5
      HT3 antagonist".
    
  